推荐活动

Nature:抗癌药物伏立诺他能够清出潜伏HIV病毒

首页 » 研究 » 新药研发 1970-01-01 转化医学网 赞(2)
分享: 
导读
来自美国北卡罗来纳大学教堂山分校的研究人员于2012年7月25日发表在《自然》期刊上的一篇开创性的研究论文,证实一种能够被用来治疗某些类型淋巴瘤的去乙酰化酶抑制剂药物---伏立诺他(vorinostat)---能够清出病人体内潜伏的HIV病毒。 研究人员开展一系列实验来评价这种药物激活和破坏潜伏的HIV病毒的潜力。起初,测量CD4+ T细胞中的活跃HIV病毒水平的实验室实验表明伏立诺他脱去这...
来自美国北卡罗来纳大学教堂山分校的研究人员于2012年7月25日发表在《自然》期刊上的一篇开创性的研究论文,证实一种能够被用来治疗某些类型淋巴瘤的去乙酰化酶抑制剂药物---伏立诺他(vorinostat)---能够清出病人体内潜伏的HIV病毒。

研究人员开展一系列实验来评价这种药物激活和破坏潜伏的HIV病毒的潜力。起初,测量CD4+ T细胞中的活跃HIV病毒水平的实验室实验表明伏立诺他脱去这些细胞中潜伏HIV病毒的伪装。接着,8名经过抗逆转录病毒疗法后保持医学上稳定的HIV病毒感染男性服用伏立诺他,然后测试他们体内活跃的HIV病毒水平,并且与服用这种药物之前的水平进行比较。

<!--more-->

研究人员发现这些接受伏立诺他治疗的病人体内CD4+ T细胞中HIV病毒RNA水平平均增加4.5倍,从而证实HIV病毒被脱去伪装。这是第一次已发布的研究证实去乙酰化酶抑制剂有潜力破除潜伏病毒库中的潜伏性。这项研究提供令人信服的证据表明人们可能采用一种新策略来直接攻击和根除潜伏的HIV病毒感染。破除HIV病毒的潜伏性只是治愈HIV病毒感染的第一步。

本文编译自<a href="http://medicalxpress.com/news/2012-07-drug-purge-dormant-hiv.html" target="_blank">Pioneering research shows drug can purge dormant HIV</a>
<div id="ztload">
<div> </div>
<div>
<div>

<img src="http://www.bioon.com/biology/UploadFiles/201207/2012072622272184.jpg" alt="" width="113" height="149" border="0" />

<a title="" href="http://dx.doi.org/10.1038/nature11286" target="_blank">doi: 10.1038/nature11286</a>
PMC:
PMID:

</div>
<div>

<br/><strong>Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy</strong><br/>


N. M. Archin, A. L. Liberty, A. D. Kashuba, S. K. Choudhary, J. D. Kuruc, A. M. Crooks, D. C. Parker, E. M. Anderson, M. F. Kearney, M. C. Strain, D. D. Richman, M. G. Hudgens, R. J. Bosch, J. M. Coffin, J. J. Eron, D. J. Hazuda, D. M. Margolis.

Despite antiretroviral therapy, proviral latency of human immunodeficiency virus type 1 (HIV-1) remains a principal obstacle to curing the infection1. Inducing the expression of latent genomes within resting CD4+ T cells is the primary strategy to clear this reservoir2, 3. Although histone deacetylase inhibitors such as suberoylanilide hydroxamic acid (also known as vorinostat, VOR) can disrupt HIV-1 latency in vitro4, 5, 6, the utility of this approach has never been directly proven in a translational clinical study of HIV-infected patients. Here we isolated the circulating resting CD4+ T cells of patients in whom viraemia was fully suppressed by antiretroviral therapy, and directly studied the effect of VOR on this latent reservoir. In each of eight patients, a single dose of VOR increased both biomarkers of cellular acetylation, and simultaneously induced an increase in HIV RNA expression in resting CD4+ cells (mean increase, 4.8-fold). This demonstrates that a molecular mechanism known to enforce HIV latency can be therapeutically targeted in humans, provides proof-of-concept for histone deacetylase inhibitors as a therapeutic class, and defines a precise approach to test novel strategies to attack and eradicate latent HIV infection directly.

<br/>来源:生物谷

</div>
</div>
</div>
评论:
评 论
共有 0 条评论

    还没有人评论,赶快抢个沙发

相关阅读